Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Advertisement
Emily MenendezUpper Tract Urothelial Carcinoma | September 22, 2023
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
Read More
Emily MenendezUpper Tract Urothelial Carcinoma | September 8, 2023
Older patients over 70 years of age need improved care and management of UTUC to improve their outcomes.
Emily MenendezUpper Tract Urothelial Carcinoma | August 17, 2023
Patients who had initiated AC 90 days after RNU were examined to determine a relation between treatment efficacy and timing.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
David Ambinder, MDUpper Tract Urothelial Carcinoma | July 31, 2023
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
Emily MenendezUpper Tract Urothelial Carcinoma | July 13, 2023
The implications of VH have been thoroughly studied in bladder cancer, but further investigation is needed in UTUC.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 7, 2023
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 7, 2023
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
Surena F. Matin, MDUpper Tract Urothelial Carcinoma | July 7, 2023
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
Katie S. Murray, DOUpper Tract Urothelial Carcinoma | July 5, 2023
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Katie S. Murray, DOUpper Tract Urothelial Carcinoma | July 5, 2023
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
Petros Grivas, MD, PhDUpper Tract Urothelial Carcinoma | June 29, 2023
ICIs for upper tract disease after upfront chemotherapy, along with the emerging role of targeted therapies.
Petros Grivas, MD, PhDUpper Tract Urothelial Carcinoma | June 29, 2023
Approaching perioperative systemic therapy in upper and lower tract disease, including neoadjuvant and adjuvant therapy.
David Ambinder, MDUpper Tract Urothelial Carcinoma | June 28, 2023
The recently released AUA/SUO guideline on UTUC includes 6 guidelines on neoadjuvant/adjuvant chemotherapy and immunotherapy.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | June 14, 2023
Assessing the treatment landscape in UTUC and how many different patient biomarkers influence treatment integration.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | June 14, 2023
A continuation of the discussion on UTUC vascular-targeted photodynamic therapy as a way of nephron-sparing for patients.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | June 14, 2023
Breaking down the differences in "high risk" and "low risk" stratification in the UTUC guideline, and other biomarkers.
Jonathan Coleman, MDUpper Tract Urothelial Carcinoma | June 14, 2023
A summary of the therapeutic strategies available for avoiding surgery for UTUC, as well as other management considerations.
Emily MenendezASCO 2023 | June 1, 2023
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
David Ambinder, MDUpper Tract Urothelial Carcinoma | May 31, 2023
There are 7 recommendations specific to the appropriateness of and proper technique for kidney-sparing management.
Advertisement
Advertisement
Advertisement